Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2010. The report specifically addresses a notifiable share interest change in OctoPlus N.V., a Dutch pharmaceuticals product and drug delivery company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than consolidated financial performance.
Material Changes
- Share Disposal: On March 18, 2010, GSK sold 25,907 ordinary shares of OctoPlus N.V.
- Ownership Reduction: GSK's interest, held by its wholly owned US subsidiary S.R. One, Limited, decreased to 5,003,710 ordinary shares.
- Percentage Stake: The reduced stake represents 14.9% of OctoPlus's total outstanding shares (33,435,432).
- Regulatory Trigger: The sale caused GSK's holding to fall below the 15% threshold required for disclosure under the Dutch Financial Supervision Act.
Outlook, Risks, and Management Commentary
Management commentary is limited to the notification of the share sale and the subsequent regulatory requirement to inform the Netherlands Authority for the Financial Markets (AFM) on March 22, 2010. The filing does not contain forward-looking guidance, general risk factors, or details on unusual items beyond this specific transaction.
Investor Verification Points
- Confirm the current ownership percentage of OctoPlus N.V. held by GSK (14.9%) and the total share count.
- Verify the date of the share sale (March 18, 2010) and the number of shares sold (25,907).
- Check for any subsequent filings regarding the AFM announcement made on March 22, 2010.
- Note that this filing does not reflect GSK's broader financial results for the period.